355 related articles for article (PubMed ID: 10961693)
1. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
Smolarz B; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B; Szewczyk T
J Exp Clin Cancer Res; 2001 Jun; 20(2):247-52. PubMed ID: 11484982
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
5. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
6. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer.
Smolarz B; Romanowicz-Makowska H; Kulig A
Acta Biochim Pol; 2003; 50(2):489-95. PubMed ID: 12833173
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
Ramón LA; Gilabert-Estellés J; Cosín R; Gilabert J; España F; Castelló R; Chirivella M; Romeu A; Estellés A
Thromb Res; 2008; 122(6):854-60. PubMed ID: 18423526
[TBL] [Abstract][Full Text] [Related]
10. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
[TBL] [Abstract][Full Text] [Related]
11. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
Emingil G; Berdeli A; Gürkan A; Han Saygan B; Köse T; Atilla G
J Clin Periodontol; 2007 Apr; 34(4):278-84. PubMed ID: 17257155
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
13. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.
Palmirotta R; Ferroni P; Savonarola A; Martini F; Ciatti F; Laudisi A; Sini V; Del Monte G; Guadagni F; Roselli M
Thromb Res; 2009 Sep; 124(4):403-8. PubMed ID: 19351570
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.
Yagmurdur MC; Atac FB; Tutar NU; Verdi H; Isiklar I; Ozdemir BH; Ozbek N; Karakayali H; Haberal M
Int Surg; 2008; 93(3):163-8. PubMed ID: 18828272
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism.
Brogren H; Wallmark K; Jern S; Karlsson L
Thromb Res; 2008; 121(6):793-7. PubMed ID: 17884148
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.
Gilabert-Estellés J; Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A
Thromb Res; 2012 Aug; 130(2):242-7. PubMed ID: 22055623
[TBL] [Abstract][Full Text] [Related]
18. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
[TBL] [Abstract][Full Text] [Related]
19. Distribution of PAI-1 promoter 4G/5G polymorphism in healthy Chinese and functional characterization using a luciferase reporter vector.
Ding Z; Pan JQ
Ann Hematol; 2005 Mar; 84(3):183-7. PubMed ID: 15309528
[TBL] [Abstract][Full Text] [Related]
20. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
